Clinical and Laboratory ObservationPharmacokinetics of Levetiracetam in Neonates with Seizures
Section snippets
Methods
The institutional review boards at Cincinnati Children's Hospital Medical Center and Good Samaritan Hospital approved the protocol and written informed consent was obtained from the legal guardian of all subjects. We prospectively enrolled infants ≤30 days of age and ≥32 weeks gestational age with seizures treated with levetiracetam who were admitted to the neonatal intensive care unit. Exclusion criteria included birth weight <2000 g and known creatinine level ≥2.0 mg/dL. Consent was obtained
Results
A total of 21 infants who received levetiracetam for clinical seizure control, electrographic seizure control, or both were screened for the study from October 2008 to May 2010, and 19 of these infants were enrolled. The two patients who were not enrolled received levetiracetam before consent could be obtained. One subject was excluded because of a laboratory error. Pharmacokinetic data included 54 levetiracetam measurements from 18 subjects. Patient characteristics are summarized in Table I.
Discussion
Levetiracetam pharmacokinetics were different in this population of neonates with seizures than in adults and older children. The half-life is 6 to 8 hours in adults4 and 5 to 7 hours in older children.12, 13 We found the median half-life to be 8.9 hours, as expected on the basis of the lower clearance of levetiracetam in neonates. The volume of distribution (Vd) is 0.5 to 0.7 L/kg in adults14 and 0.6 to 0.7 L/kg in older children.12, 13 The median Vd in our study was 0.89 L/kg. Because
References (16)
- et al.
Neonatal seizures: multicenter variability in current treatment practices
Pediatr Neurol
(2007) - et al.
Efficacy and safety of levetiracetam in infants and young children with refractory epilepsy
Seizure
(2007) - et al.
Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy
Seizure
(2005) - et al.
Levetiracetam in the treatment of neonatal seizures: a pilot study
Seizure
(2010) - et al.
Levetiracetam: safety and efficacy in neonatal seizures
Eur J Paediatr Neurol
(2011) - et al.
Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry
Clin Chim Acta
(2007) - et al.
Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab
Pharmacokinet
(2009) - et al.
Antiepileptic drugs and apoptotic neurodegeneration in the developing brain
Proc Natl Acad Sci U S A
(2002)
Cited by (63)
Sequential levetiracetam and phenytoin in electroencephalographic neonatal seizures unresponsive to phenobarbital: a multicenter prospective observational study in India
2024, The Lancet Regional Health - Southeast AsiaAcute Symptomatic Seizures in Neonates
2019, Seminars in Pediatric NeurologyNeonatal seizures (about 96 cases)
2019, Journal de Pediatrie et de PuericultureSeizure classification, etiology, and management
2019, Handbook of Clinical NeurologyAcute symptomatic neonatal seizures in preterm neonates: etiologies and treatments
2018, Seminars in Fetal and Neonatal Medicine
Supported by the National Institutes of Health (grants 5T32AR007594-15 to C.S. and 5K24HD050387 and 5U10HD037249 to A.V.). The authors declare no conflicts of interest.